Mahady Gail B, Fabricant Daniel, Chadwick Lucas R, Dietz Birgit
UIC/NIH Center for Botanical Dietary Supplements Research, Program for Collaborative Research in the Pharmaceutical Sciences, University of Illinois, Chicago, Illinois, USA.
Nutr Clin Care. 2002 Nov-Dec;5(6):283-9. doi: 10.1046/j.1523-5408.2002.05603.x.
Due to the long-term health risks now associated with hormone replacement therapy, many menopausal women are actively seeking alternative treatments. One such alternative is black cohosh (Actaea racemosa, syn. Cimicifuga racemosa), which has been used in the United States for the treatment of gynecologic complaints for more than 100 years. Review of the published clinical data suggests that black cohosh may be useful for the treatment of menopausal symptoms, such as hot flashes, profuse sweating, insomnia, and anxiety. Results from the most recently published trial, however, indicate that black cohosh is not effective for the treatment of menopausal symptoms in breast cancer survivors being treated with tamoxifen. Because the overall quality of the published clinical trials is low, two new randomized, double-blind, placebo-controlled clinical trials are currently underway in the United States. To date, only one standardized black cohosh extract has been tested clinically; the current recommended dose is 40-80 mg per day. At least 4-12 weeks of treatment may be required before any therapeutic benefits may be apparent. Adverse reactions such as nausea, vomiting, headaches, dizziness, mastalgia, and weight gain have been observed in clinical trials. No drug interactions are reported in the medical literature. The estrogenic effects of black cohosh are controversial, and the more recent data indicate that black cohosh extracts may have an anti-estrogenic activity. Owing to potential effects on sex hormones, however, black cohosh should not be administered to children or during pregnancy and lactation.
由于现在激素替代疗法存在长期健康风险,许多更年期女性正在积极寻求替代治疗方法。其中一种替代方法是黑升麻(Actaea racemosa,同义词Cimicifuga racemosa),在美国它已被用于治疗妇科疾病超过100年。对已发表的临床数据的回顾表明,黑升麻可能有助于治疗更年期症状,如潮热、多汗、失眠和焦虑。然而,最近发表的试验结果表明,黑升麻对正在接受他莫昔芬治疗的乳腺癌幸存者的更年期症状治疗无效。由于已发表的临床试验的整体质量较低,美国目前正在进行两项新的随机、双盲、安慰剂对照临床试验。迄今为止,只有一种标准化的黑升麻提取物经过了临床测试;目前推荐的剂量是每天40 - 80毫克。可能需要至少4至12周的治疗才会显现出任何治疗效果。在临床试验中观察到了诸如恶心、呕吐、头痛、头晕、乳房疼痛和体重增加等不良反应。医学文献中未报告药物相互作用。黑升麻的雌激素作用存在争议,最新数据表明黑升麻提取物可能具有抗雌激素活性。然而,由于对性激素有潜在影响,黑升麻不应给予儿童或在怀孕和哺乳期使用。